Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.10 per share.
For the full year, analysts predict revenues of $ 127.68 million, while looking forward to income of $ 0.41 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 135.00 million ~ $ 155.00 million
Click Here For More Historical Outlooks Of Catalyst Pharmaceuticals, Inc.
Previous Quarter Performance
Catalyst Pharmaceuticals, Inc. disclosed income for the second quarter of $ 0.09 per share, from the revenue of $ 29.61 million. The quarterly earnings down 10.00 percent while revenues increased 60.14 percent compared with the same quarter last year.
Street analysts expected Catalyst Pharmaceuticals, Inc. to report income of $ 0.08 per share on revenue of $ 29.48 million for the second quarter. The bottom line results beat street analysts by $ 0.01 or 12.50 percent, at the same time, top line results outshined analysts by $ 0.13 million or 0.44 percent.
Stock Performance
On Friday, shares of Catalyst Pharmaceuticals, Inc. has traded high as $ 3.32 and has cracked $ 3.14 on the downward trend, reaching $ 3.15 with volume of 1.25 million shares.
According to the previous trading day, closing price of $ 3.15, representing a 30.59 % increase from the 52 week low of $ 2.55 and a 36.93 % decrease over the 52 week high of $ 5.28.
The company has a market capital of $ 338.21 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3.
